Future Market Insights (FMI) has delivered key insights on the global pneumococcal vaccines market in its upcoming report titled “Pneumococcal Vaccines Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018 – 2028”.
In terms of revenue, the global pneumococcal vaccines market is projected to register a compound annual growth rate (CAGR) of 9.1% over the forecast period.
North America is expected to contribute a high revenue share in the global pneumococcal vaccines market over the forecast period due to increasing healthcare expenditure, favourable reimbursement policies for pneumococcal vaccination and development of new multivalent pneumococcal vaccines. Besides, the out-of-pocket cost of pneumococcal vaccines for patients with Medicare coverage is $0.00 in North America.
The global pneumococcal vaccines market is segmented based on product type, distribution channel, and regions. Based on the product type, the market is segmented into pneumococcal conjugate vaccines and pneumococcal polysaccharide vaccines.
The pneumococcal conjugate vaccines product type segment is expected to represent high revenue share in the global pneumococcal vaccines market due to growing number of research and development activities to develop new conjugate vaccines for expanding indications. Based on the distribution channel, the market is segmented into pharmacies, public health agencies, community clinics and other distribution channels. Among all the distribution channels, the public health agencies segment is expected to be the leading segment in the pneumococcal vaccines market. The revenue share of community clinics is expected to increase over the forecast period due to the growing number of community clinics.
An increasing number of the clinical trials for development of the pneumococcal vaccine is expected to provide enormous opportunities for the growth of the pneumococcal vaccines market and fulfil the demand for vaccines for multiple serotypes. Increasing government initiatives to reduce the burden of pneumococcal diseases and public–private partnerships are factors expected to fuel the growth of the pneumococcal vaccines market.
Partnerships and collaborations among manufacturers for research and development and vaccine distribution are expected to boost the growth of the pneumococcal vaccines market.
Increasing pharmacy-based immunisation services for pneumococcal vaccination and the catch up campaigns by the SAGE organization to reduce the prevalence of invasive pneumococcal disease are the major factors expected to impel the growth of the pneumococcal vaccines market. Increasing demand for pneumococcal vaccines due to immunisation programmes is expected to provide immense opportunities for the growth of the pneumococcal vaccines market.
The manufacturers of pneumococcal vaccine have reduced the pricing of the vaccines for Gavi-supported countries, which is expected to boost the demand for pneumococcal vaccines. For instance, in January 2018, Pfizer reduced the price of its PCV-13 4 dose vial vaccine for Gavi-supported countries from $3.05 to $2.95 per dose. Increasing the addition of pneumococcal vaccine in national immunisation programmes is favoring the growth of pneumococcal vaccines market.
According to the World Health Organisation (WHO) to 2017, a total 138 countries are introduced with pneumococcal vaccines in their national immunisation programme.
However, low awareness among general population regarding pneumococcal immunisation, difference in coverage of established and new vaccine, slower introduction of new pneumococcal vaccines are factors expected to hamper the growth of the pneumococcal vaccines market.
The market for pneumococcal vaccines is consolidated with very few players. Examples of some of the key players identified in the global pneumococcal vaccines market include Pfizer, Sanofi, GlaxoSmithKline, and Merck & Co.
Manufacturers are focusing on the partnerships and collaborations for expansion of their geographical presence and development of new pneumococcal vaccines. For example, in 2014 Sanofi completed a collaboration with SK Chemical Co of South Korea to co-develop pneumococcal conjugate vaccines.
Make an enquiry and contact Persistence Market Research today to get the full report.